



## Genetic Testing for Acquired Peripheral Neuropathy in Dogs

[View U.S. Patent No. 10,724,098 in PDF format.](#)

**WARF: P160048US02**

Inventors: Peter Muir, Susannah Sample, John Svaren

**The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a method for predicting acquired peripheral neuropathy in dogs, which can serve as an animal model for human therapeutic development.**

### Overview

Peripheral neuropathies are a diverse group of diseases marked by degeneration of the peripheral nervous system. These diseases affect both humans and animals. In humans, the most common form is Charcot-Marie-Tooth disease (CMT), which affects about 1 in 2,500 people. Current treatments for CMT manage symptoms rather than modify the disease course. One barrier to developing new and better treatments is the lack of a large animal model.

A related disease called acquired peripheral neuropathy (APN) syndrome is common in certain dog breeds. This condition is also referred to as laryngeal paralysis. Labrador retrievers (the most common dog breed in the United States) represent about 70 percent of APN cases, although other breeds can be affected including golden retrievers, poodles and Irish setters. To date, no genetic test for the disease is commercially available.

A diagnostic test to predict the likelihood that a patient – human or canine – will exhibit peripheral neuropathy in their lifetime would be of significant value.

### The Invention

UW–Madison researchers have identified a single nucleotide polymorphism (SNP) that is predictive of APN syndrome in dogs, based on a genome-wide association study. Using a population of Labrador retrievers (56 cases and 26 controls), the researchers have shown that a SNP on CFA1 tags the causal variant for APN in the Labrador retriever breed.

### Applications

- Genetic test for predicting dogs that will develop APN, for use in selective breeding programs and guiding treatment
- Identifying a large animal model for development of disease-modifying therapies in humans

### Key Benefits

- Potential to become the first genetic test for APN – an economically significant veterinary disease
- Potential utility for human health (e.g., genetic model for human ALS research studies)

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



**WARF**  
Wisconsin Alumni Research Foundation

| [info@warf.org](mailto:info@warf.org) | 608.960.9850

WARF believes that these technologies are especially attractive opportunities for licensing.

## Additional Information

### For More Information About the Inventors

- [Peter Muir](#)
- [John Svaren](#)

### Tech Fields

- [Animals, Agriculture & Food : Animal health](#)
- [Drug Discovery & Development : Disease models](#)

For current licensing status, please contact Emily Bauer at [emily@warf.org](mailto:emily@warf.org) or 608-960-9842

We use cookies on this site to enhance your experience and improve our marketing efforts. By continuing to browse without changing your browser settings to block or delete cookies, you agree to the storing of cookies and related technologies on your device. [See our privacy policy.](#)

OK



**WARF**  
Wisconsin Alumni Research Foundation

| [info@warf.org](mailto:info@warf.org) | 608.960.9850